Come see us at The Next Generation DX Summit, Washington, DC, August 15-18, 2017, Booth 405
A Meta-Network for Validating Liquid Biopsies Including Patients on New Immune Therapies
Pascal Puchois, Québec CEO, Trans-Hit Bio
Tuesday August 15 @12:30
Liquid biopsy has the potential to identify patients for a particular therapy and can monitor patients on therapy. This can be particularly useful for patients undergoing immune-oncology therapy. The best results are obtained using unique patient profiles, state-of-the-art processing, and specimen transport systems. Despite these efforts, the organization and conduction of large studies are slow and many times impractical. The development of an international consortium is one solution to these issues.